Cerebral Infarction Treatment Market To Reach $20.5 Billion By 2030

Cerebral Infarction Treatment Market Growth & Trends

The global cerebral infarction treatment market size is expected to reach USD 20.5 billion by 2030 and is projected to grow at a CAGR of 7.3%, according to a new report by Grand View Research, Inc. The growing prevalence of ischemic strokes, driven by an aging global population and increasing rates of lifestyle-related risk factors such as hypertension and diabetes, is a key factor in the expansion of the cerebral infarction treatment market.

According to a study published by the National Library of Medicine in March 2023, hemorrhagic stroke accounts for 10.0% to 20.0% of all strokes annually. The incidence varies significantly by region, with 8.0%-15.0% in the U.S., the UK, and Australia, and 18.0% to 24.0% in Japan and Korea. The rate of hemorrhagic stroke is notably higher in low- and middle-income countries, and among Asians. Furthermore, while stroke incidence is higher in men and increases with age, the global burden of hemorrhagic stroke is rising, particularly in African and Asian countries. Effective management of hypertension has been shown to reduce the incidence of intracerebral hemorrhage (ICH), though the fatality rate remains a concern, ranging from 25.0% to 30.0% in high-income countries and 30% to 48% in lower-income regions, highlighting disparities in critical care efficacy.

Technological advancements are significantly enhancing the treatment landscape for cerebral infarction. Innovations in thrombolytic therapies, such as tissue plasminogen activators (tPA), and development of mechanical thrombectomy devices have markedly improved patient outcomes. Moreover, the integration of artificial intelligence (AI) into diagnostic and treatment processes is revolutionizing stroke care. AI-driven algorithms now play a crucial role in predicting stroke risk and tailoring treatment strategies, which helps in personalizing care and improving overall efficacy. These advancements are not only improving the precision of treatments but also contributing to the broader adoption of advanced therapeutic options. Combined with increased investment in research and development, these technological strides are expected to drive significant growth in the cerebral infarction treatment market.

 Request a free sample copy or view report summary: Cerebral Infarction Treatment Market Report

Cerebral Infarction Treatment Market Report Highlights

• In 2023, the ischemic stroke segment held the largest share of 78.6% due to its high prevalence, technological advancements, and growing awareness of early intervention

• The tissue plasminogen activators (tPA) segment secured the largest revenue share of 39.7% in 2023, driven by its proven efficacy, widespread use, and crucial role in treating ischemic strokes

• In 2023, the hospital pharmacies segment dominated the cerebral infarction treatment market, capturing a substantial revenue share of 63.6%

Cerebral Infarction Treatment Market Segmentation

Grand View Research has segmented the cerebral infarction treatment market based on type, drug class and distribution channel:

Cerebral Infarction Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Ischemic Stroke

• Hemorrhagic Stroke

Cerebral Infarction Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Tissue Plasminogen Activators (tPA)

• Anticoagulants

• Antiplatelets

• Anticonvulsants

• Others

Cerebral Infarction Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Other

Cerebral Infarction Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Cerebral Infarction Treatment Market

• Amgen Inc.

• Pfizer Inc.

• Novartis AG

• Amneal Pharmaceuticals LLC

• Sanofi

• Abbott Laboratories

• Johnson & Johnson

• Bristol-Myers Squibb